Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives

Grazia Pennisi, Ciro Celsa, Federica Spatola, Marcello Dallio, Alessandro Federico and Salvatore Petta
Additional contact information
Grazia Pennisi: Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy
Ciro Celsa: Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy
Federica Spatola: Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy
Marcello Dallio: Department of Precision Medicine, University of Campania Luigi Vanvitelli, via Pansini 5, 80131 Naples, Italy
Alessandro Federico: Department of Precision Medicine, University of Campania Luigi Vanvitelli, via Pansini 5, 80131 Naples, Italy
Salvatore Petta: Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy

IJERPH, 2019, vol. 16, issue 22, 1-26

Abstract: The non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease as well as the first cause of liver transplantation. NAFLD is commonly associated with metabolic syndrome (MetS), and this is the most important reason why it is extremely difficult to treat this disease bearing in mind the enormous amount of interrelationships between the liver and other systems in maintaining the metabolic health. The treatment of NAFLD is a key point to prevent NASH progression to advanced fibrosis, to prevent cirrhosis and to prevent the development of its hepatic complications (such as liver decompensation and HCC) and even extrahepatic one. A part of the well-known healthy effect of diet and physical exercise in this setting it is important to design the correct pharmaceutical strategy in order to antagonize the progression of the disease. In this regard, the current review has the scope to give a panoramic view on the possible pharmacological treatment strategy in NAFLD patients.

Keywords: non-alcoholic fatty liver disease; metabolic therapy; metabolic syndrome (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/22/4334/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/22/4334/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:22:p:4334-:d:284384

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().